TipRanks on MSN
Almirall advances LAD603 phase 2 alopecia trial, adding optionality to its dermatology pipeline
Almirall SA ($GB:0O9B) announced an update on their ongoing clinical study. Study Overview: Almirall S.A. is running a phase 2 trial called “A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback